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Simple Summary: We designed a study specifically to assess the performance of genomic risk
prediction for breast cancer (BC) in older women aged ≥70 years. We assessed the effects of a
polygenic risk score (PRS) for BC and rare pathogenic variants (PVs) in BC susceptibility genes, on
incident BC risk in a prospective cohort of 6339 older women (mean age 75 years). During a median
follow-up time of 4.7 years, the PRS was an independent predictor of incident BC risk, with women
in the top quintile of the PRS distribution having over two-fold higher incident BC risk than women
in the lowest quintile. Among 41 carriers of PVs in BC susceptibility genes, we observed no incident
BC diagnoses. Our study demonstrates that a PRS still predicts incident BC risk in women aged
70 years and older, suggesting the potential clinical utility of the PRS extends to this older age group.
Abstract: Genomic risk prediction models for breast cancer (BC) have been predominantly developed
with data from women aged 40–69 years. Prospective studies of older women aged ≥70 years
have been limited. We assessed the effect of a 313-variant polygenic risk score (PRS) for BC in
6339 older women aged ≥70 years (mean age 75 years) enrolled into the ASPREE trial, a randomized
double-blind placebo-controlled clinical trial investigating the effect of daily 100 mg aspirin on
disability-free survival. We evaluated incident BC diagnoses over a median follow-up time of
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4.7 years. A multivariable Cox regression model including conventional BC risk factors was applied
to prospective data, and re-evaluated after adding the PRS. We also assessed the association of
rare pathogenic variants (PVs) in BC susceptibility genes (BRCA1/BRCA2/PALB2/CHEK2/ATM). The
PRS, as a continuous variable, was an independent predictor of incident BC (hazard ratio (HR) per
standard deviation (SD) = 1.4, 95% confidence interval (CI) 1.3–1.6) and hormone receptor (ER/PR)-
positive disease (HR = 1.5 (CI 1.2–1.9)). Women in the top quintile of the PRS distribution had over
two-fold higher risk of BC than women in the lowest quintile (HR = 2.2 (CI 1.2–3.9)). The concordance
index of the model without the PRS was 0.62 (95% CI 0.56–0.68), which improved after addition of
the PRS to 0.65 (95% CI 0.59–0.71). Among 41 (0.6%) carriers of PVs in BC susceptibility genes, we
observed no incident BC diagnoses. Our study demonstrates that a PRS predicts incident BC risk in
women aged 70 years and older, suggesting potential clinical utility extends to this older age group.
Keywords: genomics; breast cancer; risk prediction; polygenic risk score; germline
1. Introduction
Breast cancer (BC) risk prediction models may be improved by including genomic
risk scores. A polygenic risk score (PRS) aggregates the effect of many common BC
risk-associated variants into a single measure [1–4]. Common BC risk-associated ge-
netic variants used in a PRS, together, are estimated to account for 18% of familial BC
risk [5]. Predictive performance of a PRS for BC has mostly been assessed in women aged
40–69 years [1,3,6–10]. PRS performance, in terms of risk prediction in older women (aged
≥70 years), is unclear, despite a high proportion of BC diagnoses occurring in this age
group. It is also unclear whether the predictive performance of a PRS for BC attenuates
with age. Given the emerging clinical utility of PRS for BC risk prediction and stratification,
this requires further assessment.
A small proportion of women (<5%) carry rare pathogenic variants (PVs) in BC predis-
position genes, including BRCA1, BRCA2, PALB2, CHEK2 and ATM [11]. Rare PVs can be
detected by predictive clinical genetic testing and are of high clinical significance [12,13],
predisposing women to BC earlier in life [6–8,11]. Rare PVs account for ~25% of familial BC
risk [14]. Recent studies have suggested that the increase in BC risk associated with rare PVs
in high-risk genes (e.g., BRCA1, BRCA2) may decrease with increasing age [6,8,10,12,13]. If
rare PVs have age-dependent effects on BC risk, this may have important clinical implica-
tions for the appropriateness of offering predictive genetic testing to older people.
Many clinical studies have measured the association between rare PVs and BC
risk [6–8,11]. More recently, risk conferred by a 313-variant PRS for BC has been mea-
sured in meta-analysis of ten studies, with no evidence of age-related attenuation in the
predictive performance of the PRS reported [1]. The same PRS has been assessed across
several subsequent PRS validation studies [2–4]. However, participant numbers aged
≥70 years were limited. Here, we evaluate the predictive performance of (i) a PRS for BC
and (ii) rare PVs in a prospective cohort of 6339 women aged ≥70 years.
2. Materials and Methods
2.1. Study Sample
The study sample comprised female participants of the ASPirin in Reducing Events in
the Elderly (ASPREE) trial—a randomized, placebo-controlled, clinical trial investigating
the effect of daily 100mg aspirin on disability-free survival [15–17]. Study design [18,19],
recruitment [20], and baseline characteristics [21] have been published previously. The trial
recruited 19,114 individuals from Australia (n = 16,703) and the United States (n = 2411)
aged 70 years or older (≥65 years for US ethnic minorities), who, at enrolment, were
free from diagnosed cardiovascular disease events, dementia, physical disability and life-
threatening cancer diagnoses. Biospecimens and consent for genetic analysis were obtained
from 14,576 participants. The median follow-up time (randomization period) was 4.7 years
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(interquartile range 2.1 years). The study received approvals from the Alfred Hospital Re-
search Ethics Committee (Project 390/15) and is registered (NCT01038583). All participants
provided written informed consent for genetic research. The final analysis for this study
was conducted on 6339 female ASPREE participants from Australia aged ≥70 years, for
whom both genome-wide genotyping and targeted sequencing data were available.
2.2. Genome-Wide Genotyping and Polygenic Risk Score
DNA samples were genotyped using the Axiom 2.0 Precision Medicine Diversity Re-
search Array (Thermo Fisher Scientific (TFS), Waltham, MA, USA) following standard
protocols. Only participants with European genetic ancestry (>95% of female participants)
were included, to mitigate population stratification bias. Genetic ancestry was defined using
principal component analysis (PCA) based on the 1000 Genomes reference population, with
participants outside of the Non-Finnish European ancestry cluster excluded (Figure S1) [22].
Imputation was performed using the TopMED Server (European samples) [23]. After variants
with low imputation quality scores (r2 < 0.3) were excluded, a PRS was calculated based on
the 313-variant score previously described [1], using genotypes for the remaining 271 variants
(for a list of the 313 variants in the PRS, indicating the 271 variants included in the final
analysis, see Table S8). Using Plink version 1.9, we calculated the PRS for each individual as
the weighted sum of the effect size for the number of risk alleles at each variant [1].
2.3. Targeted Gene Panel Sequencing
Our custom gene panel [24] included BC predisposition genes that are incorporated
into the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algo-
rithm (BOADICEA)—BRCA1, BRCA2, PALB2, CHEK2 and ATM [11]. Following standard
protocols, DNA was extracted and sequenced using the S5TM XL system (Thermo Fisher
Scientific (TFS), Waltham, MA, USA), to average 200× depth. Variants with a ‘pathogenic’
or ‘likely pathogenic’ ClinVar annotation [25] and/or high-confidence predicted loss-of-
function in coding regions [26] were curated following ACMG/AMP Standards and Guide-
lines for the Interpretation of Sequence Variants [27], including review by two or more
laboratory scientists and a clinical geneticist. Analysis was restricted to single nucleotide
variants and small insertions/deletions.
2.4. Endpoints
The study’s primary endpoint was invasive breast cancer (BC), which included inci-
dent invasive BC diagnosed during the ASPREE trial; this was adjudicated by an expert
panel using histopathology, metastasis imaging or other clinical evidence [28]. Age at
diagnosis of prevalent BC was self-reported as before or after 50 years.
2.5. Statistical Analysis
After excluding female participants with a history of prevalent BC at enrolment,
multivariable Cox proportional hazards regression was used to evaluate the association
between PRS with incident BC by estimating the hazard ratio (HR) per standard deviation
(SD) of the PRS, after adjusting for BC family history (first-degree blood relatives), treatment
(aspirin/placebo), age at enrolment, number of children, alcohol consumption, body
mass index (BMI) at enrolment, and use of estrogen or estrogen/progesterone hormone
replacement therapy (HRT) at enrolment. Alcohol consumption was categorised into three
groupings: none (no current consumption); low (<3 drinking days per week); and high
(≥3 drinking days per week). Interaction between PRS and aspirin treatment was tested
independently alongside the complete set of covariates. BMI and number of children were
standardised to mean = 0 (SD 1).
In a separate model, PRS was categorized into three quintile-based distribution
groups—low (0–20%, Q1), moderate-risk (21–80%, Q2–4), and high-risk (81–100%, Q5). R
package pec v2019.11.03 was used for BC-free survival prediction. Net reclassification im-
provement (NRI) was calculated using R package nricens v1.6 with 1% and 3% cutoff values
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for predicting increased and decreased risk categories. We calculated cumulative incidence
estimates for each PRS group (multivariate adjusted), treating death as a competing risk.
Logistic regression was used to assess associations with prevalent breast cancer, in-
cluding family history and the presence of rare PVs as covariates. We further stratified
by diagnosis age (<50, 50+), and included number of children in the model. We used
variance inflation factor (VIF) to assess the independence of predictors, and measured the
discriminative ability of the PRS using concordance index and area under the receiver op-
erating characteristic curve (AUC). Goodness-of-fit for the logistic regression was assessed
using the Hosmer–Lemeshow (HL) test and the Tail-Based Max-test-statistic (TBM) [29].
DeLong’s test was used to compare between two correlated ROC curves [30,31]. We calcu-
lated PV ORs for prevalent BC for each gene and all five genes combined. Analyses were
performed using R v3.6.1.
3. Results
3.1. Baseline Characteristics
The mean age of the 6339 female participants of European genetic ancestry was
75.1 years at time of enrolment, with 14% aged >80 years, and 31% current or former
smokers (Table 1). The mean BMI was 28.0 kg/m2, 75% were current alcohol consumers
and 13% had a family history of BC in a first-degree blood relative. At baseline, 533 (8.4%)
participants were taking HRT (either estrogen alone or with progesterone). Six (0.2%)
were taking progesterone-only preparations. Prevalent BC was reported by 475 (7.6%)
participants, of which 60 (1%) were diagnosed before the age of 50 years.
Table 1. Characteristics of the study population.
Characteristics Total Low-Risk PRS(Q1)
Moderate-Risk PRS
(Q2–4)
High-Risk PRS
(Q5)
Participants n = 6339 n = 1268 n = 3803 n = 1268
Sex = Female (%) 6339 (100) 1268 (100) 3803 (100) 1268 (100)
Mean Age at Enrolment, Years 75.1 75.1 75.1 75.2
Age Group, Years (%)
70–74 3825 (60.3) 778 (61.4) 2287 (60.1) 760 (59.9)
75–79 1599 (25.5) 304 (24.0) 975 (25.6) 320 (25.2)
80–84 706 (11.1) 136 (10.7) 429 (11.3) 141 (11.1)
85+ 211 (3.3) 50 (3.9) 112 (2.9) 47 (3.7)
Current or Former Smoker (%) 1974 (31.1) 391 (30.8) 1195 (31.4) 388 (30.6)
Diabetes (%) 497 (7.8) 97 (7.6) 289 (7.6) 111 (8.8)
Randomized to Aspirin (%) 3170 (50.0) 630 (49.7) 1898 (49.9) 642 (50.6)
Body Mass Index kg/m2 ((mean) (SD)) 28.03 (5.09) 28.02 (5.02) 28.05 (5.10) 28.00 (5.13)
Current Alcohol Consumption (%) 4730 (74.6) 941 (74.2) 2850 (74.9) 939 (74.1)
Hormone Replacement Therapy * 533 (8.4) 103 (8.1) 321 (8.4) 109 (8.6)
Progesterone-Only HRT 6 (0.2) 1 (0.1) 3 (0.1) 2 (0.2)
Family History of Breast Cancer (%) ‡ 850 (13.4) 135 (10.6) 500 (13.1) 215 (17.0)
Prevalent Breast Cancer
Cases 475 47 288 140
Diagnosed <49 Years 60 6 39 15
Diagnosed 50+ Years 415 41 249 125
Incident Breast Cancer ¶
Cases 129 21 66 42
Polygenic Risk Score (mean (SD)) 0.1 (0.53) −0.93 (0.26) −0.13 (0.27) 0.69 (0.28)
PRS = Polygenic risk score, Q = Quintile, HRT = Hormone replacement therapy. * Estrogen alone or in combination with progesterone;
¶ Non-metastatic and metastatic events; ‡ Family history in first-degree blood relative (mother, sibling or child).
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3.2. PRS and Rare Pathogenic Variants
The PRS showed a normal distribution in the study sample with mean −0.13 (SD 0.58)
before standardization (Figure S2A), which was scaled to a mean of 0 (SD 1) for subsequent
analyses. Forty-two rare pathogenic or likely pathogenic variants (PVs) passed our variant
curation protocol (Table S1) across 41 (0.6%) participants (one participant had two PVs
detected, one each in BRCA2 and CHEK2). We identified participants with PVs in the
BRCA1 (n = 3), BRCA2 (n = 10), PALB2 (n = 6), CHEK2 (n = 7) and ATM (n = 16) genes.
Of these participants, 20% reported a family history of BC in a first-degree blood relative
at enrolment.
3.3. Incident Breast Cancer Risk
After excluding the 475 female participants with prevalent BC at enrolment, during
median follow-up (4.7 years/participant), 110 women had incident BC. None of these
women had rare PVs in the BRCA1, BRCA2, PALB2, CHEK2, and ATM genes. In the
multivariable Cox model, conventional BC risk factors, including family history of BC,
number of children, alcohol consumption and estrogen HRT were associated with risk of
incident BC (Table 2).
Table 2. Association of a polygenic risk score (PRS) with incident breast cancer (BC) risk in 6339 older women. A
multivariable Cox proportional hazards regression model was used to evaluate the association between PRS as a continuous
or categorical variable with incident BC (n = 110 cases), after adjusting for family history of BC (first-degree blood relatives),
treatment (aspirin/placebo), age at enrolment, number of children, alcohol use, BMI at enrolment and use of hormone
replacement therapy (HRT) at enrolment.
Variable
PRS as Continuous Variable PRS as Categorical Variable
Hazard Ratio 95% CI p-Value Hazard Ratio 95% CI p-Value
Polygenic Score
(per standard deviation) 1.43 (1.18; 1.73) <0.001
Low PRS (Q1) Reference
Moderate PRS (Q2,3,4) 1.16 (0.68; 2.00) 0.58
High PRS (Q5) 2.16 (1.21; 3.86) 0.009
Pathogenic Variants
(n = 41 carriers) No incident events No incident events
Family History of Breast Cancer * (Y/N) 1.81 (1.15; 2.85) 0.01 1.83 (1.16; 2.88) 0.009
Age at Enrolment 0.97 (0.92; 1.02) 0.21 0.97 (0.92; 1.02) 0.22
Treatment (Aspirin) 1.16 (0.80; 1.69) 0.44 1.15 (0.79; 1.68) 0.45
Number of Children 0.81 (0.66; 0.99) 0.04 0.81 (0.66; 0.99) 0.04
Body Mass Index (kg/m2 (mean) SD) 1.14 (0.95; 1.37) 0.17 1.14 (0.95; 1.37) 0.15
Alcohol (None) Reference Reference
Alcohol (Low) 1.16 (0.68; 1.97) 0.59 1.16 (0.68; 1.98) 0.58
Alcohol (High) 1.70 (1.01; 2.85) 0.04 1.70 (1.02; 2.86) 0.04
HRT ‡ (Y/N) 1.54 (0.88; 2.71) 0.13 1.51 (0.86; 2.65) 0.15
BMI = Body mass index, HRT = Hormone replacement therapy, PRS = Polygenic risk score, CI = Confidence Interval, SD = Standard
deviation. * Family history in first-degree blood relative (mother, sibling or child); ‡ Estrogen alone or in combination with progesterone.
The PRS, as a continuous variable in the same model, was an independent predictor of
incident BC, with a HR of 1.43 (95% confidence interval (CI) 1.18 to 1.73, p < 0.001) per SD
(Table 2, Figure 1), after adjustment for covariates. The PRS was also an independent pre-
dictor of incident hormone receptor (ER/PR)-positive BC (HR = 1.5 (CI 1.2–1.9), p < 0.001),
after adjustment for covariates. The VIF for each term in the multivariable model was
less than 1.1, indicating the independence of the predictors. The concordance index of the
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model without the PRS was 0.62 (95% CI 0.56 to 0.68), which improved after addition of the
PRS to 0.65 (95% CI 0.59 to 0.71). We found no evidence of an interaction between aspirin
treatment and the PRS.
Figure 1. Association of a polygenic risk score (PRS) with incident and prevalent breast cancer (BC)
risk in 6339 older women. We evaluated incident BC diagnoses over a median follow-up of 4.7 years
and prevalent BC diagnosed pre-enrolment (self-reported). A multivariable Cox regression model
including conventional risk factors examined the association between incident BC risk and the PRS as
a categorical variable by quintiles (Q) of the distribution (low- (Q1), medium- (Q2–4), high- (Q5) risk
groups), adjusting for family history of BC (first-degree blood relatives), treatment (aspirin/placebo),
age at enrolment, number of children, alcohol consumption, body mass index (BMI) at enrolment,
and use of estrogen or estrogen/progesterone hormone replacement therapy (HRT) at enrolment.
Logistic regression examined associations with prevalent BC, adjusting for family history of BC
(first-degree blood relatives) and pathogenic variants in BC-associated genes, represented by odds
ratio (OR).
We categorized the PRS into low- (Q1), moderate- (Q2–4) and high-risk (Q5) groups
to consider PRS effect on incident BC. When using Q1 as a reference, participants in the
high-risk PRS group had a significantly higher risk of developing incident BC compared
to women in the low-risk PRS group (HR = 2.16 (95% CI 1.21 to 3.86), p < 0.01) (Table 2,
Figure 2). The competing risk model showed that individuals in Q5 (the high-risk group)
had higher cumulative incidence than those in Q1 (the low-risk group) and Q2–4 (the
moderate-risk group) (Figure 2). Participants in the moderate- and low-risk groups did
not have significantly different risks of incident BC. The calibration plot for the incident
risk model (Figure S2B) illustrates high concordance between the predicted and observed
events. Net reclassification analysis had point estimates of 0.15 (95% CI 0.03; 0.24) for
combined change, with NRI+ of 0.09 (95% CI −0.02; 0.13) and NRI− of 0.05 (95% CI 0.02;
0.08). Reclassification of cases and controls is shown in Table S2.
Histopathology was available for 103 incident BC cases (Table S3). The PRS was found
to be a significant predictor of (ER+/PR+) disease (HR = 1.53 per SD (95% CI 1.22 to 1.91)),
p < 0.001, n = 79).
3.4. Prevalent Breast Cancer
Of the 41 participants with PVs, 11 (27.5%) reported prevalent BC at baseline, com-
pared with 7.5% (475/6339) in all female participants, giving an estimated OR of 4.69 (95%
CI 2.21 to 9.27, p < 0.001) for PVs grouped across all five genes (Table S4). The OR estimate
for PVs in BRCA1 and BRCA2 (OR = 6.09 (95% CI 1.77 to 19.08)) was higher than PVs in the
other genes (ATM/PALB/CHECK2) (OR = 3.33 (95% CI 1.19 to 7.92), p = 0.011). Per gene
ORs are reported in Table S5, but are limited by small carrier numbers.
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Figure 2. Competing risk survival curves for incident breast cancer according to PRS groups. The
PRS distribution was categorized by quintiles (Q) of the distribution into three groups: low-risk
(Q1, green), medium-risk (Q2–4, brown) and high-risk (Q5, red). Competing risk estimates of the
cumulative incidence were calculated for each group, adjusting for the following covariates: family
history of BC (first-degree blood relatives), treatment (aspirin/placebo), age at enrolment, number
of children, alcohol consumption, body mass index (BMI) at enrolment, and use of estrogen or
estrogen/progesterone hormone replacement therapy (HRT) at enrolment.
In sub-group analysis, when stratifying prevalent BC cases by diagnosis age (before
or after 50 years), the OR estimate for having a PV was higher for early onset BC risk
(diagnosed <50 years, OR = 9.79 (CI 2.29 to 28.87), p = 0.02) than for later-onset BC risk
(diagnosed >50 years, OR = 3.91 (CI 1.64 to 8.31), p = 0.02) (Table S6).
The PRS as a continuous variable was associated with prevalent BC after controlling
for covariates in the model (OR = 1.47 per SD (95% CI 1.34 to 1.61), p < 0.001). The HL
and TBM tests did not indicate a lack of goodness-of-fit (p > 0.05). The AUC for the model
with the PRS (AUC = 0.62 (0.59–0.65), Figure S2C) was improved relative to the model
including family history of BC only (AUC = 0.53 (0.52–0.55), Figure S2D) (p < 0.01). When
considering the PRS as a categorical variable, participants in the high-risk group had a
significantly higher BC risk compared with the low-risk group (OR = 3.16 (95% CI 2.26 to
4.49), p < 0.001). Participants in the moderate-risk group also had higher BC risk versus the
low-risk group (OR = 2.12 (95% CI 1.56 to 2.94), p < 0.001).
3.5. Modification of BC Risk by PRS in Rare PV Carriers
Eleven participants with PVs reported prevalent BC, and 29 with PVs reported no
prevalent BC. We hypothesized that individuals with PVs and a history of BC (affected)
may have a higher PRS, on average, than those with PVs but without BC (unaffected), as
suggested by previous BRCA1/BRCA2 studies [32]. However, we observed no evidence of
over-representation of affected or unaffected carriers between low-, moderate- or high-risk
PRS groups (Chi-squared χ2 = 1.97, df = 2, p = 0.37) (Figure 3, Table S7).
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Figure 3. PRS distribution of female pathogenic variant (PV) carriers who were affected (red) or
unaffected (blue) by prevalent BC. Density represents the proportion of individuals in each PRS
group (low/medium/high). The PRS is distributed normally according to scaled PRS score (mean 0,
standard deviation 1). PV carriers are highlighted across the PRS distribution.
4. Discussion
In this study, we assessed the performance of a 313-variant PRS for BC and rare
pathogenic variants in BC-susceptibility genes for risk prediction of BC in older women.
We found that the PRS was a significant predictor of incident BC risk, when considered as
both a continuous (per SD) or categorical (low, moderate and high-risk groups) variable.
Net reclassification was improved after addition of the PRS to a model composed of
traditional BC risk factors. Older women in the highest quintile of the PRS distribution had
over two-fold higher risk of incident BC than those in the lowest quintile. The PRS was
also associated with incident hormone receptor positive (ER+/PR+) disease specifically,
and with prevalent BC. The emerging clinical utility of PRS for BC risk prediction and risk
stratification, previously demonstrated in women aged 40–69 years [1–4], therefore likely
extends to older women.
The PRS effect (HR = 1.4 per SD) was similar to that reported in population-based
studies of younger women [1,3,9,10], including a recent meta-analysis measuring the same
PRS used in our study across ten prospective studies of younger women where ORs ranged
from 1.48 to 1.75 across participants of all ages [1]. Subsequent validation studies of the
same PRS in other cohorts found similar ORs to our study (~1.4) [2–4]. Notably, the average
age at enrolment in the ASPREE female population (75 years) is over 15 years older than
most other prior population-based studies, including the UK Biobank population, where
average enrolment age was 58 years [33]. Yet, similar HRs for the PRS were observed
between ASPREE and these prior studies. This suggests that the predictive performance of
the PRS does not attenuate with age, in women over 70 years.
No incident BC diagnoses were observed in 41 women with rare PVs, despite the high
expected BC risk conferred by these PVs (e.g., average cumulative risk to age 70 years of
50–70% for BRCA1/BRCA2 PVs) [8]. This challenges the clinical value of predictive genetic
testing for BC risk by sequencing of these genes alone in women aged ≥70 years. However,
genetic testing for BC in older women can trigger cascade family testing, which has benefits
including risk management, early detection, and/or prevention of cancer in younger family
members. We also observed no incident ovarian cancer diagnoses in the 41 PV carriers.
Retrospective data suggested a higher risk of BC in individuals with a PV compared
with those without (OR = 4.7) when all PVs across all genes were combined into a single
group. This reflects the effect of PVs earlier in life. However, women with PVs diagnosed
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with cancer earlier in life are less likely to have been ascertained by our study, because they
either died from cancer before the enrolment age or were too unwell to enrol in the ASPREE
trial due to a current or recent cancer diagnosis. This has likely resulted the healthy selection
bias that can often occur in older survivor cohorts [34]. Thus, risk estimates observed in PV
carriers ascertained in our study (and the ORs and CIs reported for associations between
the PRS/PVs and prevalent cases) must be interpreted with caution.
In response to recent studies reporting that an individual’s PRS may modify the
penetrance of rare PVs in the BRCA1 and BRCA2 genes [9,10,32,35], we sought evidence of
risk modification by the PRS in PV carriers affected and unaffected by prevalent BC in our
study. We observed no evidence of either a higher PRS in females with a PV and affected
by BC, or conversely a protective effect of a lower PRS in unaffected PV carriers (Figure 3).
However, we acknowledge our analysis was limited by a relatively small number of PV
carriers. Further studies are needed to investigate this more rigorously.
Clinically, it is notable that most incident BC cases in our study had favourable
prognoses (e.g., hormone receptor positive). This raises the possibility that genomic risk
prediction for BC in older women may have limited impact for improving survival, and
that this impact must be balanced against potential overdiagnosis/overtreatment risks in
this older demographic.
Key strengths of our study include the well-characterised, older study population
(median age after follow-up: 78 years) followed prospectively, with all incident BC diag-
noses adjudicated by an expert panel. Most previous studies of genetic risk scores for BC
have examined younger cohorts, some selected for family history.
Limitations of our study include the unavailability of some phenotypic and clinical
risk factors associated with BC, such as mammographic density, reproductive factors (e.g.,
age at menarche, menopause, first birth) and hormonal factors beyond HRT use (e.g.,
oral contraceptive use) [36]. Our clinical risk factor model might be improved with these
additional factors. Some participants may have undergone risk-reducing bilateral pro-
phylactic mastectomy or bilateral salpingo-oophorectomy prior to enrolment, to reduce
BC/OC risk. The relatively small number of PVs detected (n = 41) necessitated grouping of
PVs across genes to calculate averaged risk, despite known differences in the magnitude
of risk conferred by PVs in different genes [12,13]. Prevalent BC (pre-enrolment) was
self-reported (without specific diagnosis age) and not verified through supporting docu-
mentation, potentially causing over-estimation of prevalent BC events. Our study involved
only participants of European genetic ancestry, meaning results may not be generalisable
to other populations.
5. Conclusions
In conclusion, we demonstrate that the predictive value of a PRS for BC extends to
older women, with no evidence of age-related attenuation in predictive performance after
the age of 70 years. Our study has clinical implications for the use and interpretation of
polygenic risk prediction of BC across the female lifespan.
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